Metformin Use in Patients With Historical Contraindications
Abstract
Editorials7 February 2017Metformin Use in Patients With Historical ContraindicationsKasia J. Lipska, MD, MHSKasia J. Lipska, MD, MHSFrom Yale School of Medicine, New Haven, Connecticut.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/M16-2712 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Patients with type 2 diabetes rarely have just 1 chronic condition to manage (1). Some comorbid conditions, such as kidney disease, heart failure, and liver dysfunction, greatly reduce the number of drugs that can be used safely to lower blood glucose levels. As a result, patients with these conditions often end up on medications that increase the risk for hypoglycemia and weight gain (sulfonylureas or insulin), result in a high treatment burden (insulin), or substantially increase the cost of treatment (all newer, branded products). For these patients, a safe and inexpensive oral agent, minimally disruptive to their routines, would be ...References1. Piette JD, Kerr EA. The impact of comorbid chronic conditions on diabetes care. Diabetes Care. 2006;29:725-31. [PMID: 16505540] CrossrefMedlineGoogle Scholar2. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with metformin [Letter]. N Engl J Med. 1998;338:265-6. [PMID: 9441244] CrossrefMedlineGoogle Scholar3. Inzucchi SE, Masoudi FA, McGuire DK. Metformin in heart failure…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.